Physician profile
Patrick H Rask
NPI 1427188309
$6,990.02
in general payments reported to CMS, 2019-2025
31 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,400 · 2020: $689 · 2021: $1,011 · 2022: $1,850 · 2023: $1,256 · 2024: $507 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,315 · Travel and Lodging: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,314.75 |
| Travel and Lodging | $724.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,944.47 | 2021-2024 | Intellis Adaptivestim |
| Relievant Medsystems, INC. | $967.73 | 2023 | Intracept |
| Boston Scientific Corporation | $949.82 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Abbott Laboratories | $790.47 | 2019 | |
| Nalu Medical, INC. | $671.56 | 2021-2025 | Nalu Neurostimulation System |
| Amgen INC. | $244.37 | 2019-2021 | |
| Nevro Corp. | $202.19 | 2019-2024 | Senza |
| Allergan, INC. | $157.61 | 2019-2021 | |
| Curonix LLC | $113.28 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.63 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $106.76 | 2021 | |
| Spr Therapeutics, INC | $87.00 | 2021 | |
| Si-Bone, INC. | $75.95 | 2019-2022 | |
| Lilly USA, LLC | $71.75 | 2019-2020 | |
| Abbvie INC. | $69.90 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $64.04 | 2019-2021 | |
| Bioventus LLC | $40.98 | 2021-2024 | Durolane |
| Stimwave Technologies Incorporated | $39.92 | 2020 | |
| Daiichi Sankyo INC. | $39.26 | 2019 | |
| Mdd US Operations, LLC | $28.86 | 2020 | |
| Pfizer INC. | $27.85 | 2019-2020 | |
| Vertos Medical, INC. | $26.83 | 2021 | |
| Avanos Medical | $26.67 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $26.56 | 2020-2021 | |
| Medtronic USA, INC. | $20.25 | 2020 | |
| Biotronik Nro, INC. | $19.60 | 2025 | Prospera |
| Fidia Pharma USA INC. | $15.94 | 2020 | |
| Globus Medical, INC. | $15.33 | 2025 | Senza |
| Painteq LLC | $14.04 | 2021 | |
| Mml US, INC. | $10.01 | 2025 | Reactiv8 |
| Stratus Medical, LLC | $8.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Rask listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.